Stonebridge Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Stonebridge Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-150	Closed	-$13K	–	1092
2022 Q1	$13K	Hold	150	–	–	﹤0.01%	630
2021 Q4	$17K	Hold	150	–	–	﹤0.01%	545
2021 Q3	$19K	Hold	150	–	–	﹤0.01%	508
2021 Q2	$20K	Hold	150	–	–	﹤0.01%	501
2021 Q1	$20K	Buy	+150	New	+$22.5K	﹤0.01%	507
2019 Q3	–	Sell	-708	Closed	-$62K	–	947
2019 Q2	$62K	Buy	+708	New	+$60.4K	0.01%	286
2015 Q3	–	Sell	-59,598	Closed	-$5.01M	–	155
2015 Q2	$5.01M	Sell	59,598 -1,017	-2%	-$79.1K	1.93%	12
2015 Q1	$4.56M	Buy	60,615 +1,740	+3%	+$122K	1.76%	13
2014 Q4	$3.66M	Buy	58,875 +3,198	+6%	+$182K	1.5%	13
2014 Q3	$2.9M	Buy	55,677 +2,481	+5%	+$126K	1.28%	21
2014 Q2	$2.73M	Buy	53,196 +2,268	+4%	+$102K	1.23%	27
2014 Q1	$2.42M	Buy	50,928 +3,450	+7%	+$177K	1.18%	30
2013 Q4	$2.06M	Buy	+47,478	New	+$1.97M	1.06%	34

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Stonebridge Capital Advisors's XBI Position: Q2 2022 in Review

Stonebridge Capital Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 150 shares — an estimated $13K sold.

Stonebridge Capital Advisors first reported a position in XBI in Q4 2013 and held it in 13 quarters. The position peaked at $5.01M in Q2 2015. 704 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Stonebridge Capital Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
Stonebridge Capital Advisors sold 150 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $13K.
Stonebridge Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2013 and held it in 13 quarters.
Stonebridge Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $5.01M in Q2 2015.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.